A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.
Also called NCT01104701
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 121 participants
- Sponsor
- Registry
-
NCT01104701
-
- Other papers using this trial's data
- Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01104701. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2014-07-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- exenatide once weekly
- Intervention (Drug)
- exenatide once monthly suspension
- Intervention (Drug)
- exenatide once monthly suspension
- Intervention (Drug)
- exenatide once monthly suspension
- Lead sponsor
- AstraZeneca
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01104701- Content hash
3128a548692afb689aff65f93929cb335b61615c1fc0f748f14dd29406c0f962